1. Home
  2. MYPS vs ALXO Comparison

MYPS vs ALXO Comparison

Compare MYPS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PLAYSTUDIOS Inc.

MYPS

PLAYSTUDIOS Inc.

HOLD

Current Price

$0.49

Market Cap

62.3M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.49

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYPS
ALXO
Founded
2011
2015
Country
United States
United States
Employees
568
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.3M
68.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MYPS
ALXO
Price
$0.49
$2.49
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$2.00
$3.42
AVG Volume (30 Days)
326.4K
872.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.02
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.41
52 Week High
$1.79
$2.66

Technical Indicators

Market Signals
Indicator
MYPS
ALXO
Relative Strength Index (RSI) 37.64 66.55
Support Level $0.48 $2.20
Resistance Level $0.50 $2.66
Average True Range (ATR) 0.04 0.31
MACD -0.00 0.03
Stochastic Oscillator 28.00 82.18

Price Performance

Historical Comparison
MYPS
ALXO

About MYPS PLAYSTUDIOS Inc.

PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: